Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.

Author information

Affiliations

  • 1. Rinat Laboratories, Pfizer Inc., South San Francisco, California.
      Authors
    • Dorywalska M 1
    • Farias SE 1
    • Lui V 1
    • Hasa-Moreno A 1
    • Casas MG 1
    • Tran TT 1
    • Delaria K 1
    • Liu SH 1
    • Foletti D 1
    • Pons J 1
    • Shelton DL 1
    • Rajpal A 1
    • Strop P 1
    (13 authors)
  • 2. Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut.
      Authors
    • Dushin R 2
    • Moine L 2
    • Zhou D 2
    • Navaratnam T 2
    • O'Donnell CJ 2
    (5 authors)

ORCIDs linked to this article

Molecular Cancer Therapeutics, 04 Mar 2016, 15(5):958-970
https://doi.org/10.1158/1535-7163.mct-15-1004 PMID: 26944918 

Abstract 

The degree of stability of antibody-drug linkers in systemic circulation, and the rate of their intracellular processing within target cancer cells are among the key factors determining the efficacy of antibody-drug conjugates (ADC) in vivo Previous studies demonstrated the susceptibility of cleavable linkers, as well as auristatin-based payloads, to enzymatic cleavage in rodent plasma. Here, we identify Carboxylesterase 1C as the enzyme responsible for the extracellular hydrolysis of valine-citrulline-p-aminocarbamate (VC-PABC)-based linkers in mouse plasma. We further show that the activity of Carboxylesterase 1C towards VC-PABC-based linkers, and consequently the stability of ADCs in mouse plasma, can be effectively modulated by small chemical modifications to the linker. While the introduced modifications can protect the VC-PABC-based linkers from extracellular cleavage, they do not significantly alter the intracellular linker processing by the lysosomal protease Cathepsin B. The distinct substrate preference of the serum Carboxylesterase 1C offers the opportunity to modulate the extracellular stability of cleavable ADCs without diminishing the intracellular payload release required for ADC efficacy. Mol Cancer Ther; 15(5); 958-70. ©2016 AACR.

Full text links 

Read article at publisher's site: https://doi.org/10.1158/1535-7163.mct-15-1004

Read article for free, from open access legal sources, via Unpaywall: https://mct.aacrjournals.org/content/molcanther/15/5/958.full.pdfUnpaywall

Citations & impact 

Impact metrics

71
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/44257332
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/44257332

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1158/1535-7163.mct-15-1004

Supporting
Mentioning
Contrasting
9
163
1

Article citations

Go to all (71) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.